Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Authors
Weber, JD'Angelo, S
Minor, D
Hodi, F
Gutzmer, R
Neyns, B
Hoeller, C
Khushalani, N
Miller, W
Lao, C
Linette, G
Thomas, L
Lorigan, Paul C
Grossmann, K
Hassel, J
Maio, M
Sznol, M
Ascierto, P
Mohr, P
Chmielowski, B
Bryce, A
Svane, I
Grob, J
Krackhardt, A
Horak, C
Lambert, A
Yang, A
Larkin, J
Affiliation
Moffitt Cancer Center, Tampa, FL, USA.Issue Date
2015-04
Metadata
Show full item recordAbstract
Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have progressed after ipilimumab and BRAF inhibitors. We assessed the efficacy and safety of nivolumab compared with investigator's choice of chemotherapy (ICC) as a second-line or later-line treatment in patients with advanced melanoma.Citation
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. 2015, 16 (4):375-84 Lancet OncolJournal
Lancet OncologyDOI
10.1016/S1470-2045(15)70076-8PubMed ID
25795410Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(15)70076-8